ERBB2 and breast carcinoma: Our findings support evidence demonstrating that growth factor receptors, such as insulin-like growth factor receptor (IGF-1R), EGFR, and ErbB2, play critical roles in the mediation of endocrine resistance in breast cancer [41–44].